Economic burden of cancer across the European Union: a population-based cost analysis.

By R. Luengo-Fernandez, J. Leal, A. Gray, R. Sullivan. The Lancet Oncology, 2013

960 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/be96805613ba4e6fe372fe4c8fbd9a5e66fdfcf9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Cherny
2. R. Sullivan
3. E. D. Vries
4. Christoph C. Zielinski
5. U. Dafni
6. M. Piccart
7. J. Kerst
8. A. Sobrero

Citations in the corpus

• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “This is especially true in Europe where the costs of care delivery [6] and cancer outcomes [7-9] vary substantially across Europe with the latter being influenced by the level”